<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIDANOSINE (DDI)</span><br/>(di-dan'o-sine)<br/><span class="topboxtradename">Videx, </span><span class="topboxtradename">Videx EC<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">nucleoside reverse transcriptase inhibitor</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg, 150 mg, 200 mg tablets; 125 mg, 200 mg, 250 mg, 400 mg delayed release capsules; 100 mg, 167 mg, 250 mg, 2 g, 4 g powder for oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>DDI interferes with the HIV RNA-dependent DNA polymerase (reverse transcriptase), thus preventing replication of the virus.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Synthetic purine nucleotide that inhibits replication of HIV.</p>
<h1><a name="uses">Uses</a></h1>
<p>Advanced HIV infection in patients who are intolerant to zidovudine (AZT) or who demonstrate significant clinical or immunological
         deterioration during zidovudine therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any of the components in the formulation, pregnancy (category B), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Individuals with peripheral vascular disease, history of neuropathy, chronic pancreatitis, renal impairment, or any liver
         impairment.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 kg, tablets, 250 mg q.d. or 125 mg b.i.d. (take 2 tablets at each dose to ensure adequate buffering); 60 kg, powder, 167 mg b.i.d.; <img src="../images/special/greaterorequal.gif"/><i>60 kg</i>, tablets, 400 mg q.d. or 200 mg b.i.d.; <img src="../images/special/greaterorequal.gif"/><i>60 kg</i>, powder, 250 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 120 mg/m<sup>2</sup> b.i.d., 1 y, give a 1-tablet dose; &gt;<i>1 y</i>, give a 2-tablet dose<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug on an empty stomach. Food should not be consumed within 1530 min of drug administration.</li>
<li>Give with water. Do <small>NOT</small> give with fruit juice or any other acid-containing liquid.
         </li>
<li>Chewable tablets must be thoroughly chewed or crushed and dispersed in at least 30 mL (1 oz) of water and immediately swallowed.</li>
<li>Mix powder for oral solution (buffered) with at least 120 mL (4 oz) of water, stir until dissolved (requires 23 min),
            and immediately swallowed.
         </li>
<li>
            				Note: Powder for oral solution (pediatric) is prepared by pharmacist to yield a concentration of 10 mg/mL. Shake solution thoroughly
            before administration.
            			
         </li>
<li>Dosage reduction may be indicated in those with renal or hepatic impairment.</li>
<li>Store reconstituted liquid in a tightly closed container in refrigerator for up to 30 d.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Palpitations, thrombophlebitis, arrhythmias, <span class="speceff-common">vasodilation</span>. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness, nervousness, insomnia, peripheral neuropathy,</span> lethargy, poor coordination, seizures. <span class="typehead">Special Senses:</span> Retinal depigmentation, photophobia, blurred vision, optic neuritis, diplopia, blindness. <span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain, nausea, vomiting, diarrhea,</span> constipation, stomatitis, dry mouth, <span class="speceff-life">pancreatitis</span>, increased liver enzymes. <span class="typehead">Hematologic:</span> Increased WBC, neutrophil, lymphocyte, and platelet counts; increased Hgb, thrombocytopenia, ecchymosis, hemorrhage, petechiae. <span class="typehead">Metabolic:</span> Hypocalcemia, hypokalemia, hypomagnesemia, hyperuricemia (asymptomatic), <span class="speceff-common">hypertriglyceridemia</span>. <span class="typehead">Musculoskeletal:</span> Muscle atrophy, myalgia, arthritis, decreased strength. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Asthma, cough, dyspnea, epistaxis, rhinitis, rhinorrhea,</span> hypoventilation, pharyngitis, rhonchi or rales, sinusitis, congestion. <span class="typehead">Skin:</span> Rash, impetigo, eczema, <span class="speceff-common">pruritus, sweating,</span> erythema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">aluminum</span>- and <span class="classification">magnesium-containing antacids</span> may increase the aluminum- and magnesium-associated adverse effects of tablets. The effectiveness of <b>dapsone</b> in prophylaxis of <i>Pneumocystis carinii</i> pneumonia may be reduced by concomitant didanosine. May cause additive neuropathy with <b>zalcitabine</b> (ddC). <span class="typehead">Food:</span> Absorption is significantly decreased by food. Take on an empty stomach. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract when administered to fasting patient with antacids; 2340% reaches systemic circulation. <span class="typehead">Peak:</span> 0.61 h. <span class="typehead"> Distribution:</span> Distributed primarily to body water; 21% reaches CSF; crosses placenta. <span class="typehead">Elimination:</span> 36% excreted in urine. <span class="typehead">Half-Life:</span> 0.81.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of pancreatitis (e.g., abdominal pain, nausea, vomiting, elevated serum amylase). Report immediately to physician
            and withhold drug until ruled out.
         </li>
<li>Monitor for S&amp;S of peripheral neuropathy (e.g., numbness, tingling, burning, pain in hands or feet). Report to physician;
            dose reduction may be indicated.
         </li>
<li>Monitor patients with renal impairment for drug toxicity and hypermagnesemia manifested by muscle weakness and confusion.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately to physician any of the following: Abdominal pain, nausea, or vomiting.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>